financetom
Business
financetom
/
Business
/
LVMH veteran Michael Burke to head US and other operations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LVMH veteran Michael Burke to head US and other operations
Jul 7, 2025 12:32 PM

PARIS (Reuters) -Luxury goods group LVMH has named longtime executive Michael Burke, one of CEO Bernard Arnault's most trusted advisers, as head of LVMH Americas, the company's unit for North and South America, Arnault said in a memo to staff on Monday.

Burke, 68, has held top management positions at Dior, Fendi, Bulgari and Louis Vuitton in over 40 years working with Arnault.

His appointment comes as the luxury industry faces a deep downturn, with economic pressures and price fatigue weighing on appetite for high-end goods in China and the United States.

Hopes for a U.S. -led turnaround at the start of the year were dashed by weakening demand there, with trade tensions further clouding the outlook.

Arnault, who attended the inauguration of U.S. President Donald Trump in January and has met with Trump since then, has said that the European Union must soften its stance toward U.S. trade demands and negotiate a deal to avoid tariffs and protect European jobs.

Burke will report to LVMH Managing Director Stephane Bianchi, and the executives in charge of U.S. and Latin America operations will report to Burke.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With AIM ImmunoTech Stock Friday?
What's Going On With AIM ImmunoTech Stock Friday?
Mar 20, 2026
AIM ImmunoTech Inc. ( AIM ) shares slipped on Friday after more than doubling recently, following a sharp rally driven by final approval from the Japan Patent Office for its Ampligen-based cancer treatment. Patent Approval Details The newly approved Japanese patent covers Ampligen with anti-PD-1 or anti-PD-L1 inhibitors for cancer treatment. It includes multiple oncology applications, including pancreatic cancer, with...
What's Going On With AIM ImmunoTech Stock Friday?
What's Going On With AIM ImmunoTech Stock Friday?
Mar 20, 2026
AIM ImmunoTech Inc. ( AIM ) shares slipped on Friday after more than doubling recently, following a sharp rally driven by final approval from the Japan Patent Office for its Ampligen-based cancer treatment. Patent Approval Details The newly approved Japanese patent covers Ampligen with anti-PD-1 or anti-PD-L1 inhibitors for cancer treatment. It includes multiple oncology applications, including pancreatic cancer, with...
American Eagle Gold Closes a $23-Million Investment by Eric Sprott
American Eagle Gold Closes a $23-Million Investment by Eric Sprott
Mar 20, 2026
11:11 AM EDT, 03/20/2026 (MT Newswires) -- American Eagle Gold ( AMEGF ) on Friday said it raised $23 million from a private-placement offering of 19.2-million flow-through shares at $1.20 each sold to mining magnate Eric Sprott. Sprott acquired the shares at a back-end price of $0.77, for a 9.9% equity stake in the company. He becomes the third strategic...
Accenture's Fiscal Q2 Results 'Solid' and Ahead of Expectations, RBC Says
Accenture's Fiscal Q2 Results 'Solid' and Ahead of Expectations, RBC Says
Mar 20, 2026
10:43 AM EDT, 03/20/2026 (MT Newswires) -- Accenture's ( ACN ) fiscal Q2 financial results were solid and ahead of analyst expectations, but its fiscal Q3 guidance missed estimates, RBC Capital Markets analysts said in a Thursday note. Accenture ( ACN ) expects fiscal 2026 spending trends to remain similar to a year earlier, which RBC analysts note is a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved